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Abstract: Nasal congestion is a common symptom in rhinitis (both allergic and nonallergic), 
rhinosinusitis and nasal polyposis. Congestion can also be caused by physical obstruction of nasal 
passages and/or modulation of sensory perception. Mucosal inflammation underlies many of the 
specific and interrelated factors that contribute to nasal congestion, as well as other symptoms of 
both allergic rhinitis and rhinosinusitis. A wide range of biologically active agents (eg, histamine, 
tumor necrosis factor-α, interleukins, cell adhesion molecules) and cell types contribute to 
inflammation, which can manifest as venous engorgement, increased nasal secretions and tissue 
swelling/edema, ultimately leading to impaired airflow and the sensation of nasal congestion. 
Inflammation-induced changes in the properties of sensory afferents (eg, expression of peptides 
and receptors) that innervate the nose can also contribute to altered sensory perception, which 
may result in a subjective feeling of congestion. Increased understanding of the mechanisms 
underlying inflammation can facilitate improved treatment selection and the development of 
new therapies for congestion.
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Introduction
Nasal congestion or obstruction is one of the most frequent symptoms encountered in 
primary care and specialist clinics, and it is often the predominant symptom in upper 
respiratory tract disorders, such as allergic rhinitis, rhinosinusitis, nonallergic rhinitis, 
and nasal polyposis. Additionally, nasal congestion is also a common symptom in otitis 
media and asthma, and it can contribute to the onset or worsening of sleep disturbances, 
including obstructive sleep apnea.1
The pathophysiology of nasal congestion, which may be best described as a percep-
tion of reduced nasal airflow or a sense of facial fullness, involves a number of under-
lying mechanisms. These include mucosal inflammation, often involving increased 
venous engorgement, increased nasal secretions, and tissue swelling/edema; physical 
problems affecting the structure of the nasal passage; and/or modulation of sensory 
perception. Many inflammatory and neurogenic mediators contribute to plasma exuda-
tion and vasodilatation, with resultant edema and swelling of the nasal mucosa. Vari-
ous technological advancements including rhinomanometry and acoustic rhinometry, 
offer complementary tools to qualitatively and quantitatively study the nasal airway, 
providing greater insight into the physiological fluctuations and pathophysiological 
mechanisms that influence nasal patency.2,3
The purpose of this article is to review the various pathophysiological mechanisms 
that contribute to objective nasal congestion or the perception of nasal congestion.International Journal of General Medicine 2010:3 48
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Mucosal inflammation
Mucosal inflammation is the central pathophysiological 
mechanism that underlies many of the specific and inter-
related factors that contribute to congestion, including 
increased venous engorgement, increased nasal secretions 
and tissue swelling/edema.4 In the following sections, we 
will provide examples of parts of the inflammatory process, 
rather than encyclopedic coverage of the pathophysiological 
processes associated with each disease.
Inflammation associated with allergic rhinitis and rhino-
sinusitis can reduce the physical size of the nasal passages by 
inducing vasodilatation, increasing blood flow and increasing 
vascular permeability. The result is engorgement of nasal 
venous sinusoids, swelling of the anterior and inferior turbi-
nates and obstruction of nasal airflow, ultimately contributing 
to nasal congestion.5 In addition, some patients are unable 
to adequately control sinusoid venous engorgement, which 
may be due to conditions such as Horner’s syndrome, nasal 
reflex sympathetic dystrophy, rhinitis medicamentosa, and 
treatment with α-adrenergic antagonists.6–8 More frequently, 
however, sinonasal venous engorgement and inflammation 
are associated with common upper respiratory tract disorders, 
such as allergic rhinitis and rhinosinusitis.
Allergic rhinitis
The prevalence of allergic rhinitis is increasing world-
wide, occurring in 10% to 30% of adults and up to 45% of 
children.9–11 Nearly 50% of patients with allergic rhinitis 
experience symptoms for 4 months of the year, and nasal 
congestion is frequently the predominant symptom. Other 
symptoms of allergic rhinitis include nasal itching, rhinor-
rhea, and sneezing, as well as ocular itching, redness, and 
tearing.12
Although inflammation and tissue swelling/edema are 
frequent components of other common upper respiratory tract 
disorders, such as rhinosinusitis, the underlying inflamma-
tory mechanisms have been primarily studied in the setting 
of allergic rhinitis. Symptoms of allergic rhinitis, including 
nasal congestion, are primarily due to a combination of the 
early and late-phase allergic inflammatory response.13–18 
In a sensitized host, an antigen comes into contact with the 
nasal mucosa, leading to crosslinking of immunoglobulin E 
(IgE) receptors on mast cells. This results in degranulation 
of these cells and the release of histamine and proteases from 
preformed granules.13–15 In addition, an array of early-phase 
proinflammatory molecules are synthesized and released, 
most notably leukotrienes, prostaglandins, tumor necrosis 
factor (TNF)-α, and interleukin (IL)-4.13,19,20 Release of 
these inflammatory mediators leads to swelling/edema and 
fluid secretion, resulting in congestion as well as other nasal 
symptoms.19
A large body of literature supports a role for leukotrienes 
as mediators in allergic rhinitis. Cysteinyl leukotrienes can 
be recovered in nasal secretions after exposure to natural 
allergens21 and at elevated concentrations in allergic rhinitis 
with increased allergen dose exposure (Figure 1a).22 Chal-
lenge with cysteinyl leukotriene also increases nasal airway 
resistance (Figure 1b).23 In addition, cysteinyl leukotrienes 
may facilitate the maturation of eosinophil precursors and 
act as eosinophil chemoattractants, promoters of eosinophil 
adhesion, and inhibitors of eosinophil apoptosis.20
Like leukotrienes, thromboxanes are arachidonic acid 
derivatives, released from mast cells and other inflammatory 
cells, that are found in nasal lavage fluid samples following 
nasal allergen challenge.24,25 In animal models, TXA2 ago-
nists increase nasal airway resistance and vascular perme-
ability.25 TXA2 receptor antagonists have also been shown 
to improve congestion in animals and reduce nasal mucosal 
swelling in AR patients following allergen challenge.24,25
Prostaglandin D2 (PGD2) is the major prostanoid pro-
duced in the acute phase of allergic reactions, and it is 
thought to be associated with hypertrophic inflammation 
in the nose and recruitment of eosinophils.26 A number 
of other biomarkers of inflammation, including tryptase, 
N-alpha-tosyl L-arginine methyl ester (TAME)-esterase and 
eosinophil cationic protein (ECP), are also detectable in the 
nasal mucosa within minutes to hours after allergen chal-
lenge. These mediators stimulate the early phase response 
and also lead to increased venous engorgement, which results 
in concomitant rhinorrhea and nasal congestion.19
The chronic, late-phase inflammatory response involves 
cellular infiltration, which sustains tissue swelling and edema, 
further exacerbating congestion.13–15 As a result of cytokine 
or mediator release, the nasal mucosa becomes infiltrated 
with inflammatory cells including eosinophils, neutrophils, 
basophils, mast cells, and lymphocytes, that sustain and 
exacerbate the nasal mucosal inflammatory reaction.20
Eosinophils are the predominant cell type in the chronic 
inflammatory processes that characterize the late-phase 
allergic response, and they release a broad array of pro-
inflammatory mediators, including cysteinyl leukotrienes, 
ECP, eosinophil peroxidase, and major basic protein.15,20 
These cells may also serve as a major source of IL-3, 
IL-5, granulocyte-macrophage colony-stimulating factor 
(GM-CSF), and IL-13.20 IL-5 is an eosinopoietic cytokine that 
promotes eosinophil differentiation and maturation within International Journal of General Medicine 2010:3 49
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Figure 1 Clinical data support a role for leukotrienes as mediators of congestion in allergic rhinitis. A) Cysteinyl leukotrienes (cys-LT) can be recovered at elevated levels in 
nasal secretions with increased allergen dose exposure in patients with allergic rhinitis. aversus baseline. bversus previous pollen dose and baseline.   Adapted with permission 
from Creticos PS, Peters SP,   Adkinson NF Jr, Naclerio rM, Hayes eC, Norman PS. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J 
Med. 1984;310(25):1626–1630.22 Copyright © 1984 Massachusetts Medical Society.   All rights reserved. B) Challenge with cysteinyl leukotriene increases nasal airway resistance 
(NAr). aP  0.05 vs baseline.   Adapted with permission from Okuda M,  watase T, Mezawa A, Liu CM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy. 1988;60(6):537–540.23 
Copyright © 1988 American College of Allergy,   Asthma and Immunology.
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the bone marrow.27 Circulating eosinophils are increased 
in number in subjects with allergic disorders, and infiltra-
tion at the site of provocation has been generally attributed 
to influx of mature cells. However, there appears to be a 
subset of eosinophil progenitor cells that undergo local 
maturation in the nasal mucosa, also in an IL-5-dependent 
fashion.27 Eosinophil infiltration has been demonstrated to 
have a significantly negative correlation with nasal airflow 
in patients with allergic rhinitis.28 The cellular infiltration of 
the late-phase response also primes the mucosa for additional 
antigen exposure and increases the response to it, thus further 
exacerbating symptoms upon continued exposure (eg, as the 
allergy season progresses).29
In addition to eosinophils, other inflammatory cells, 
eg, basophils, mast cells, T cells, also accumulate within the 
nasal epithelium during the late-stage response.13,15 Leukocyte 
activation, with subsequent migration to sites of inflamma-
tion, leads to changes in the cell membrane (eg, increased 
integrin expression) that result in adhesion to the endothe-
lial surface.30 Survival of cells that have been recruited and International Journal of General Medicine 2010:3 50
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migrated to sites of inflammation, particularly eosinophils 
and mast cells, is enhanced by epithelial generation of 
GM-CSF, IL-5, and stem cell factor (SCF).30,31 Cultured nasal 
epithelial cells have been shown to generate SCF in vitro, 
and levels of this growth factor are increased in nasal lavage 
fluids from patients with seasonal allergic rhinitis.30
TNF-α is a key inflammatory mediator of the late-phase 
response, and its levels have been shown to be dramatically 
increased beginning at about 1 hour after allergen challenge.19 
Plasma exudation and preferential upregulation of neutrophils 
over eosinophils during the late phase are characteristic of the 
response to TNF-α.32 This cytokine has been demonstrated 
to activate T cells, endothelial cells, fibroblasts, and macro-
phages to express cell surface receptors and to release addi-
tional inflammatory cytokines.13,14,19 TNF-α also increases the 
expression of cell adhesion molecules (intercellular adhesion 
molecule 1 [ICAM-1] and vascular cell adhesion molecule 1 
[VCAM-1]).19 Proinflammatory interleukins (IL-1β, IL-6, 
and IL-8) are elevated in patients with allergic rhinitis and 
have been shown to promote the activation of immune cells 
as well as to enhance expression of receptors for cell adhesion 
molecules (eg, selectins, integrins).19 These events, along with 
IgE synthesis and eosinophil/basophil priming, collectively 
contribute to inflammation, venous engorgement, nasal 
hyperreactivity, and symptoms of allergic rhinitis, including 
congestion.19,33
Nonallergic rhinitis (that which is not mediated by 
an IgE response) includes infectious rhinitis, vasomotor 
rhinitis, nonallergic rhinitis with eosinophilia syndrome 
(NARES), and hormonal rhinitis (that precipitated by preg-
nancy and menstrual irregularities). In particular, significant 
nasal congestion may be present with pregnancy-related 
rhinitis.34
rhinosinusitis
Rhinosinusitis is now the accepted term for a group of dis-
orders characterized by inflammation of the mucosa of the 
nasal passages and paranasal sinuses. Although the term itself 
is specific, rhinosinusitis may be due to an array of etiologic 
agents, including microorganisms; noninfectious, nonim-
munologic causes; and allergic and nonallergic immunologic 
inflammation.34,35
The most common cause of rhinosinusitis is viral infec-
tion (often referred to as the common cold).36 A large body of 
research supports the view that symptoms of the common cold 
are not due to direct cytopathic effects of the viral infection. 
Rather, it appears that viral infection stimulates inflammatory 
pathways that, once activated, tend to prolong symptoms 
even after viral replication has been ablated.37 In addition, 
an estimated 0.5% to 2% of cases of viral rhinosinusitis are 
complicated by secondary bacterial infections.35
Regardless of etiology, rhinosinusitis is typically clas-
sified as acute or chronic, depending on duration of symp-
toms.38 Although microorganisms play a predominant role in 
the etiology of acute rhinosinusitis, the role of infection in 
patients with chronic rhinosinusitis is controversial (although 
in a subset of chronic rhinosinusitis patients, fungi may play 
a role).35 Furthermore, allergic and immunologic factors 
have also been shown to be associated with the develop-
ment of rhinosinusitis; eg, perennial allergic rhinosinusitis 
is a documented predisposing condition for acute bacterial 
rhinosinusitis.39
The pathogenesis of rhinosinusitis, like that of allergic 
rhinitis, includes secretion of proinflammatory cytokines. 
In patients with acute rhinosinusitis, levels of inflammatory 
cytokines and total protein are significantly increased in nasal 
lavage fluid compared with healthy controls (Figure 2).40 
Kinin levels have also been found to be markedly increased in 
the nasal secretions of patients with acute viral rhinosinusitis, 
and elevated levels of IL-1, IL-6, and IL-8 have also been 
detected in the nasal secretions of these patients.4,41 Kinins 
can act on blood vessels to cause vascular leakage and/or 
engorgement, and they also stimulate afferent nerve fibers 
in the nasal mucosa, leading to hyperresponsiveness.4,42,43 
In addition, TNF-α and other proinflammatory cytokines 
are elevated during the course of naturally acquired acute 
viral upper respiratory tract infection.44 Similar to allergic 
rhinitis, acute rhinosinusitis is also associated with signifi-
cantly increased infiltration of inflammatory cells, including 
neutrophils and T cells, in the nasal epithelium and lamina 
propria.45
The pathophysiology of chronic rhinosinusitis is not fully 
understood; however, the cytokine and mediator profile in 
this condition closely resembles the profile found in acute 
rhinosinusitis, with the exception of a small but significant 
increase in ECP.38 Nasal tissue samples taken from patients 
with chronic rhinosinusitis have been shown to have increased 
levels of leukotrienes C4, D4, and E4 and higher levels of mark-
ers of eosinophilic inflammation, such as ECP (Figure 3).46 
In addition, a number of studies have reported that markers 
of atopy are more prevalent in populations with chronic 
rhinosinusitis.47–49 Although the role of allergy in chronic 
rhinosinusitis remains controversial, it has been postulated 
that swelling of the nasal mucosa in allergic rhinitis may 
restrict ventilation and obstruct sinus ostia, leading to mucus 
retention and infection.47International Journal of General Medicine 2010:3 51
Nasal congestion pathophysiology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Nasal polyposis
Nasal polyposis is a chronic inflammatory disease of the upper 
airway characterized histologically by the infiltration of inflam-
matory cells, most notably eosinophils.50 The cause or causes of 
nasal polyposis are not clear but may involve chronic infection, 
aspirin intolerance, alteration in aerodynamics with trapping of 
pollutants, epithelial disruptions, epithelial cell defects, or inhal-
ant or food allergies.51,52 This condition may affect as much as 4% 
of the population,53 and its symptoms include nasal obstruction, 
nasal discharge, and impairment of sense of smell.47
Congestion in nasal polyposis is related to edema for-
mation secondary to inflammatory processes similar to 
those described above for allergic rhinitis and rhinosinus-
itis. Numerous studies have demonstrated the presence of 
eosinophils and related mediators in patients with allergic 
or nonallergic nasal polyposis. These mediators include 
IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α, RANTES, GM-CSF, 
granulocyte colony-stimulating factor, ECP, eotaxin, and 
interferon (IFN)-γ (Figure 4).54–57 Increased levels of metal-
loproteinases and destruction of extracellular matrix due to 
chronic inflammation are also thought to play a significant 
role in the pathobiology of nasal polyposis.58
The pattern of inflammatory markers in nasal polyposis 
differentiates this disease from chronic rhinosinusitis. T-cell 
response in CRS exhibits a Th1 pattern, in which interferon 
(IFN)-g, transforming growth factor-b1 (50) and IL-3 (51) are 
key players. A Th2 pattern predominates in nasal polyposis, 
characterized by IgE production, infiltration of eosinophils and 
upregulation of cytokines and mediators, including IL-5, ECP 
and eotaxin, that drive eosinophil response.59 Staphylococcus 
aureus enterotoxins may play a role in the pathophysiology 
of NP. S. aureus colonization is higher in patients with NP 
compared to those with CRS, and IgE antibodies to S. aureus 
enterotoxins have been associated with higher levels of inter-
leukin (IL)-5, eotaxin and eosinophil cationic protein (ECP).59 
Nasal exposure to S. aureus enterotoxin B was shown to aug-
ment eosinophilic inflammation, IgE production, and cytokine 
production in mice,60 and recent data demonstrated that the 
stimulation of human NP tissue with S. aureus enterotoxin 
B significantly induced production of proinflammatory cyto-
kines, with a shift toward a Th2 pattern of expression.61
Structural problems
Nasal congestion can also occur secondary to structural 
causes, such as septal deviation, choanal atresia, concha bul-
losa, cleft palate, adenoid hypertrophy, and neoplasia.34,62–66 
The anterior nasal valve is the narrowest part of the airway, 
and inspiratory airflow through the nose can be compromised 
by the size of this nasal opening and the shape/structure of 
the nasal passages. Septal deviation may also cause impaired 
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airflow and the symptom/perception of nasal congestion. 
However, significant anatomic variance exists across indi-
viduals; anterior deflections affecting the nasal valve have 
the greatest impact on airflow, while those in the middle 
and inferior part of the nasal cavity have little effect on 
airflow resistance.67 Adenoid hypertrophy is another example 
of physical obstruction that can affect airflow, particularly in 
children, and it may also contribute to otitis media.63
The recumbent position can influence both the perception 
of nasal obstruction and objective measurements of nasal 
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volume and nasal cross-sectional area in normal subjects, as 
well as in patients with rhinitis.68 It has been suggested that 
the nasal mucosa reaction to venous changes that alter local 
blood flow, secondary to compression of the neck veins or 
hydrostatic pressures, may give rise to this phenomenon. The 
perception of nasal obstruction induced by lying down seems 
to be greater in subjects with symptoms of rhinitis.68
Secondary inflammation may result from neurologic 
responses that involve a wide range of neurotransmitter 
systems. The nasal mucosa is invested with sensory, parasym-
pathetic and sympathetic nerves, and they may all contribute 
to reflex activation of glands or neurogenic inflammation. 
Sensory nerves generate sensations, including pruritus, and 
provide the afferent limb for motor reflexes, such as sneezing. 
Parasympathetic and sympathetic reflexes can affect both 
glandular and vascular function in the nose. Neural function 
can be chronically upregulated in the presence of mucosal 
inflammation. This may lead to neural hyperresponsiveness 
and neurogenic inflammation, which is thought to result from 
the release of peptides (eg, substance P, calcitonin gene-
related peptide [CGRP], neurokinin A) from the peripheral 
terminals of nociceptive sensory nerve fibers. The molecular 
mechanisms underlying hyperresponsiveness are not fully 
understood but are thought to involve actions of neurotroph-
ins on sensory afferents.43,69 The interplay of these molecules 
and the pathological processes they stimulate induce or exac-
erbate many typical upper respiratory symptoms, including 
congestion (Figure 5).43
Modulation of sensory perception
The sensory nerves of the nose arise from the olfactory nerve, 
as well as from the ophthalmic and maxillary branches of 
the trigeminal nerve. Nonolfactory sensory nerves consist of 
both myelinated and unmyelinated (primarily nociceptive) 
fibers.43 Physical and chemical stimuli, as well as endogenous 
biochemical products, can stimulate sensory afferents in the 
Figure 5 Generation of nasal symptoms through neural pathways. Sensory nerves can be stimulated by products of allergic reactions and by external physical and chemical 
irritants. Signals are transmitted to the central nervous system (CNS), where they can trigger sensations (pruritus) and can further travel through secondary synapses to 
activate efferent motor (sneezing) and autonomic neurons.   Action potentials traveling through parasympathetic efferent nerves can lead to glandular activation and rhinor-
rhea, as well as to some vasodilatation. Suppression of sympathetic neural output, on the other hand, results in vasodilatation and nasal congestion.   Antidromic stimulation of 
sensory nerves with release of tachykinins and other neuropeptides at the nasal mucosa contributes to symptom development with glandular activation, vasodilatation, and 
plasma extravasation. Neuropeptide release can also lead to leukocyte recruitment and activation. Collectively, events generated by the antidromic stimulation of sensory 
nerves constitute the phenomenon of “neurogenic inflammation”. Reprinted from J Allergy Clin Immunol,   vol 118, Sarin S, Undem B, Sanico A, Togias A, The role of the nervous 
system in rhinitis, Pages 999–1016, Copyright 2006, with permission from American Academy of Allergy, Asthma and Immunology.43
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nasal mucosa to carry sensations (eg, pruritus) to the central 
nervous system and also activate reflexes (eg, sneezing).43 
It should be noted that symptoms typical of rhinitis can be pro-
duced through neural mechanisms without any demonstrable 
mucosal abnormality.43 In addition, mentholated vapors can 
influence the perception of relief from congestion without 
actually altering airflow. This effect is thought to be due to 
activation of cold receptors by menthol, and this cool sensa-
tion creates the impression of increased airflow.70 Conversely, 
patients with complete turbinectomy (“empty nose”) may 
still complain of the perception of nasal congestion.66,71 The 
importance of events initiated by the nervous system is further 
underscored by the many patients with perennial nonallergic 
rhinitis who complain of nasal congestion in the absence of 
any demonstrable abnormalities in the mucosa.72
Role of specific neural pathways  
in rhinitis symptoms
Specific symptoms of rhinitis are mediated by the actions 
of distinct neural pathways. Sensory axons can be classified 
according to size, conduction velocity, the neurotransmitters 
they release, and the different types of stimuli to which they 
are sensitive. Small unmyelinated fibers (C fibers) conduct 
action potentials slowly and are generally responsive to 
noxious mechanical and chemical stimuli. Thinly myelinated 
Aδ fibers are also nociceptors. Larger myelinated Aβ fibers 
have more rapid conduction velocities and may convey non-
nociceptive information. Pruritus is a tactile sensation that is 
conveyed to the central nervous system via trigeminal fibers 
that have their cell bodies in the trigeminal ganglion.43,69
Trigeminal neuronal activation caused by mast cell media-
tors may also contribute to sneezing and itching. Calcitonin 
gene-related peptide (CGRP), a potent vasodilator that may 
play a role in congestion, is also associated with trigeminal 
activation and is increased in nasal lavage fluids following 
allergen challenge. Support for the role of trigeminal activa-
tion in the development of AR symptoms is seen in a recent 
study in which inhalation of CO2, a known inhibitor of both 
neuronal activation and CGRP release, significantly improved 
nasal allergy symptoms, including congestion.73
Abnormalities in parasympathetic reflex arcs may also 
contribute to the development of rhinorrhea and congestion. 
It has been suggested that vasomotor, idiopathic, or “irritant” 
rhinitis may result from increased sensitivity of afferent fibers 
to irritant stimuli and/or augmented glandular responses to 
activation by parasympathetic axons.69
Increased understanding of the neurotransmitters and 
other modulators released by different primary afferents has 
led to the realization that these neurons can also be classified 
on the basis of the molecules they use to communicate 
with other cells. Primary afferents can also be differenti-
ated on the basis of the specific receptors they express and 
thus the substances to which they are sensitive. A small 
subset of C fibers that express histamine H1, and perhaps 
also H4, receptors convey information that gives rise to the 
sensation of itch.74,75 Another subset of C fibers expresses 
transient receptor potential vanilloid-1 (TRPV1) receptors. 
Primary afferents expressing these receptors are thought 
to be involved in detection of painful heat stimuli.76 These 
receptors are also involved in the development of thermal 
hyperalgesia that may occur secondary to inflammation.77 In 
addition to sensing thermal stimuli, primary afferents with 
TRPV receptors also convey information about mechanical 
stimuli and changes in local osmolarity.78
A growing body of evidence has indicated that the neu-
rotransmitter phenotypes of primary afferent neurons are 
highly plastic and may change rapidly as a function of expo-
sure to inflammatory stimuli. This inflammatory neuroplastic-
ity is the consequence of a combination of activity-dependent 
changes in the neurons and specific molecules that initiate 
particular signal transduction pathways.79 An inflammation-
induced release of mediators can change the properties of 
primary sensory neurons, producing alterations in sensitivity 
and changes in transmitter phenotypes. For example, inflam-
mation results in a nerve growth factor–dependent increase 
in substance P expression in C fibers and novel expression 
of this neuropeptide in some large Aβ fibers, which do not 
normally contain this peptide.79 Alterations of this type may 
contribute to the sensation of congestion in the absence of 
impaired breathing or blocked nasal passages. This sugges-
tion is supported by the observation that nasal responsive-
ness to histamine and capsaicin (a highly specific stimulus 
for C fibers) is increased in subjects with allergic rhinitis.80 
It has also been noted that patient perception of idiopathic 
rhinitis improves with long-term exposure to capsaicin, an 
agent that desensitizes nerves but has no effect on inflamma-
tory mediators. These data support the view that alterations 
in sensory processing may play a role in the pathophysiology 
of congestion in some cases.81,82
Summary
Nasal obstruction or congestion is one of the most com-
mon symptoms encountered in primary care and specialist 
clinics, and it is the symptom that is most bothersome to 
patients. Mucosal inflammation is the primary pathophysi-
ological mechanism leading to congestion in common upper International Journal of General Medicine 2010:3 55
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respiratory diseases, such as allergic rhinitis, rhinosinusitis, 
and nasal polyposis. Mucosal inflammation in these condi-
tions is responsible for many of the distinct and interrelated 
factors that contribute to congestion, including increased 
venous engorgement, elevated nasal secretions, and tissue 
swelling/edema. In addition, mechanical and structural fea-
tures of the sinonasal passages (eg, septal deviation, choanal 
atresia, concha bullosa and adenoid hypertrophy) can result 
in blockage/obstruction/congestion. Importantly, neurogenic 
mechanisms also contribute significantly to the pathophysi-
ological changes underlying nasal congestion, and abnormal 
primary afferent signaling may give rise to the sensation of 
congestion even in the absence of inflammation and impaired 
airflow. A greater understanding of the pathophysiological 
mechanisms underlying congestion, in particular the mucosal 
inflammation associated with common conditions such as 
allergic rhinitis and rhinosinusitis, has the potential to help 
clinicians and researchers optimize treatment with existing 
therapies and develop new treatments for these conditions.
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